ACUTE HEPATITIS С ON THE BACKGROUND OF LIVER Cirrhosis IN THE OUTCOME OF CHRONIC HEPATITIS C: CLINICAL CASE
https://doi.org/10.21518/2079-701X-2017-20-118-123
Abstract
A patient with Child-Pugh B cirrhosis as the outcome of chronic hepatitis C (HCV), genotype 1b was treated with ombitasvir/ paritaprevir/ritonavir/dasabuvir (Viekira Pak) and ribavirin (Ribavirin-SZ) for 12 weeks with achievement of sustained virological response. 48 weeks after the end of the antiviral treatment the patient developed acute viral hepatitis with high level of liver aminotransferases caused by the hepatitis C virus genotype 3a. On day 18 of hospitalization antiviral therapy with sofosbuvir 400 mg per day and daclatasvir 60 mg per day for 12 weeks was administered. Drug tolerance was good, biochemical and sustained virological response was achieved.
About the Authors
V. G. Morozov
Medical Company Hepatolog.
Russian Federation
Russian Federation
MD, Prof.
Samara.
E. S. Malova
Medical Company Hepatolog.
Russian Federation
Russian Federation
MD.
Samara.
L. M. Topornina
Medical Company Hepatolog.
Russian Federation
Samara.
Russian Federation
Samara.
E. V. Jarkova
Medical Company Hepatolog.
Russian Federation
Samara.
Russian Federation
Samara.
A. A. Ribkina
Medical Company Hepatolog.
Russian Federation
Samara.
Russian Federation
Samara.
L. N. Finko
Medical University Reaviz.
Russian Federation
Russian Federation
MD.
Samara.
A. M. Kalishenko
Samara Regional Center for the Prevention and Control of AIDS and Infectious Diseases.
Russian Federation
Samara.
Russian Federation
Samara.
P. E. Tkachenko
First Moscow State Medical University named after I.M.Semashko, MoH RF.
Russian Federation
Moscow.
Russian Federation
Moscow.
A. A. Ishmukhametov
First Moscow State Medical University named after I.M.Semashko, MoH RF; Chumakov Federal Scientific Center for Research and Development of Immune-and- Biological Products of Russian Academy of Sciences.
Russian Federation
MD, Prof, corresponding member of the RAS.
Russian Federation
MD, Prof, corresponding member of the RAS.
References
1. World Health Organization. Global alert and response (GAR). Hepatitis C. [Internet]. Geneva: World Health Organization; 2002. Available from: http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index4.htm1.
2. World Gastroenterology Organisation Practice Guideline Diagnosis, Management and Prevention of Hepatitis C 2017 Update. Available from: http://www.worldgastroenterology.org/guidelines/global-guidelines/hepatitisc/hepatitis-c-english.
3. World Health Organization. Hepatitis C. [Internet]. World Health Organization; Updated October 2017. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/.
4. Seeff LB. Natural history of chronic hepatitis C. Hepatology, 2002 Nov, 36(5 Suppl 1): S35-46.
5. Centers for Disease Control and Prevention [Internet]. Hepatitis C FAQs for Health Professionals [Page last reviewed: January 27, 2017]. Available from: https://www.cdc.gov/hepatitis/hcv/hcvfaq.htm#section1.
6. rospotrebnadzor.ru [Интернет] Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека. Доступно с: http://rospotrebnadzor.ru/.
7. 63rospotrebnadzor.ru [Интернет] Управление федеральной службой по надзору в сфере защиты прав потребителей и благополучия человека по Самарской области; с 2006. Доступно с: http://63.rospotrebnadzor.ru/.
8. Camma C, Almasio P, Craxi A. Interferon as treatment for acute hepatitis C. A meta-analysis. Dig Dis Sci, 1996, 41: 1248–1255.
9. Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology, 2003, 125: 80–88.
10. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat, 2006, 13: 34–41.
11. Poynard T, Regimbeau C, Myers RP, Thevenot T, Leroy V, Mathurin P, et al. Interferon for acute hepatitis C. Cochrane Database Syst Rev, 2002, 1CD000369.
12. EASL Recommendations on Treatment of Hepatitis C 2016. European Association for the Study of the Liver. J Hepatol, 2016 Sep 12, pii: S01688278(16)30489-5. doi:10.1016/j.jhep.2016.09.001.
13. Министерство здравоохранения Российской Федерации. Рекомендации по диагностике и лечению взрослых больных гепатитом С. М., 2014. 75 с.
14. Deterding K, Spinner C, Schott E, Welzel T, Gerken G, Klinker H, et al. Six weeks of sofosbuvir/ledipasvir (SOF/LDV) are sufficient to treat acute hepatitis C virus genotype 1 monoinfection: the HEPNET acute HCV IV study. J Hepatol, 2016, 64: S211.
15. Base PP, Shah NJ, Aloysius MM, Brown Jr R. Sofosbuvir and ledipasvir vs.sofosbuvir and simeprevir for acute hepatitis C: a RCT (SLAM C study). Hepatol Int, 2016, 10: S14–S15.
16. Rock Stroh JK, Bhagani S, Hyland RH, Yun C, Zheng W, Brainard D, et al. Ledipasvir/sofosbuvir for 6 weeks in HIV-infected patients with acute HCV infection. Conference on Retroviruses and Opportunistic Infections (CROI), February 22–25, Boston, Massachusetts.
Review
For citations:
Morozov VG, Malova ES, Topornina LM, Jarkova EV, Ribkina AA, Finko LN, Kalishenko AM, Tkachenko PE, Ishmukhametov AA. ACUTE HEPATITIS С ON THE BACKGROUND OF LIVER Cirrhosis IN THE OUTCOME OF CHRONIC HEPATITIS C: CLINICAL CASE. Meditsinskiy sovet = Medical Council. 2017;(20):118-123. (In Russ.) https://doi.org/10.21518/2079-701X-2017-20-118-123
Views:
1821
Email this article 